Saturday, May 10, 2025
5/10/2025
Multiscale Systems to Elucidate Susceptibility and Cardioprotective Mechanisms in Cardio-oncology - PROJECT SUMMARY (OVERALL) The overarching goal of this Program Project Grant (PPG) is to elucidate mechanisms of cardiotoxicity and to develop a platform to test cardiotoxicity of new cancer therapeutics. Project 1 (Moslehi) will use a combination of mouse- and cell-based models to address the central question of whether cardiotoxicity associated with ibrutinib is on- or off-target. Project 2 (Wu) will establish novel pooled “cell villages” from patients to map genetic inter-individual difference in response to kinase inhibitors to elucidate genetic susceptibility to cardiotoxicity from kinase inhibitors. Project 3 (Mercola) aims to identify mechanisms that protect against cardiotoxicity of ibrutinib using a pipeline for discovery of protective targets based on reverting epigenomic consequences of exposure to a toxic drug. All three projects will be supported by an iPSC Processing Core (Core B) (Sallam) that will facilitate a unique repository of iPSC lines from patients with ibrutinib treatment. An Administrative Core (Wu) will support all three projects and the core to facilitate a fully integrated program project and enable high- impact research. The proposed PPG and assembled group collectively introduces synergies that will significantly impact the field of cardio-oncology and make translationally actionable inroads to decrease the burden of adverse effects of cancer therapeutics.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).